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Purpose: To report a case of optic neuropathy and retinopathy from a dose of radiation traditionally
thought to be safe to the visual system and discuss strategies for preventing vision loss when using
radiation to treat intraocular tumors.
Observations: A 44-year-old woman presented with new, painless vision loss in the left eye eighteen
months after receiving proton beam radiotherapy (20 Gy dose delivered in two 10 Gy fractions) for a
uveal metastasis of lung cancer. The dilated funduscopic examination revealed optic disc swelling and
retinal hemorrhages and an MRI of the brain and orbits demonstrated enhancement of the left optic
nerve head, ﬁndings consistent with radiation optic neuropathy (RON) and retinopathy. Risk factors for
developing RON included coincident use of oral chemotherapy and relatively large fractionated doses of
radiation.
Conclusions and importance: Though cumulative radiation doses to the anterior visual pathway of less
than 50 Gy are traditionally felt to be safe, it is important to consider not just the total exposure but also
the size of individual fractions. The single-dose threshold for RON in proton beam treatment has yet to be
deﬁned. Our case suggests that fractions of less than 10 Gy should be delivered to minimize the risk of
optic nerve injury.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ionizing radiation is frequently used in the treatment of brain,
sinus, orbital, and intraocular tumors, and a small percentage of
patients develop vision loss as a consequence of bystander injury to
the anterior visual pathway. Radiation optic neuropathy (RON) is
thought to result from dysfunction of the vascular endothelium,
with endothelial cell loss leading to breakdown of the blood-brain
barrier and subsequent exudation, vascular occlusion, and hypo-
xia.1e6 Vision loss from radiation is typically delayed, occurring an
average of 18 months following treatment.5,6
Fortunately, the risk of RON is thought to be low at cumulative
radiation doses of less than 50 Gy, though this threshold may be
lower in patients receiving concurrent chemotherapy or with tu-
mors compressing the optic nerves or chiasm.5e7 We report a case
of a patient who developed RON and retinopathy from a relativelyor, Boston, MA 02118, United
eeler).
Inc. This is an open access article ulow dose (20 Gy) of proton beam radiation, delivered in two 10 Gy
fractions.2. Case report
A 44-year-old woman with a history of non-small cell lung
cancer (NSCLC) with uveal metastases e treated 18 months prior
with a 20 Gy dose of proton beam radiotherapy to the left macula
(Fig. 1), delivered in two 10 Gy fractions e presented with a three-
day history of new, painless vision loss in the left eye. Visual acuity
was 20/20, right eye and 20/40, left eye. There was dyschroma-
topsia and an afferent pupillary defect on the left. Intraocular
pressures were normal bilaterally and the anterior segment ex-
amination was unremarkable.
Ophthalmoscopy revealed swelling of the left optic nerve with
adjacent nerve ﬁber layer hemorrhage and scattered dot-blot
hemorrhages throughout the macula (Fig. 2). Also clearly
apparent on the funduscopic examination were several small,
white subretinal lesions along the vascular arcades in the periph-
eral retina of the right eye and a larger chorioretinal scar in thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Radiation dosage map. The red outline indicates the tumor, the cross is the fovea, and the yellow disc is the optic nerve head, which received 100% of the treatment dose. The
black circle represents the equator, the yellow circle is the ora serrata, and the green circle is the limbus. (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
Fig. 2. Fundus photos on presentation. A. Peripheral subretinal lesions in the right fundus. B. Optic disc edema, retinal hemorrhages, and a macular scar in the left fundus.
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ously diagnosed uveal metastases. Comparison to prior fundus
photographs demonstrated stability of these lesions since the time
of proton beam treatment and initiation of maintenance oral
chemotherapy (crizotinib) 18 months earlier.Humphrey visual ﬁeld testing revealed an area of inferonasal
depression near ﬁxation in the left eye corresponding to the mac-
ular scar. MRI of the brain and orbits with gadolinium demon-
strated enhancement at the left optic nerve head consistent with
RON (Fig. 3). Her new visual symptoms, optic nerve swelling, and
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nerve and retina.
Five weeks following presentation with RON, the patient
returned with sudden worsening of her vision on the left. Visual
acuity was 20/20, right eye and 20/600, left eye. Repeat ophthal-
moscopy demonstrated neovascularization of the disc and a vitre-
ous hemorrhage.
Over the next three months, her vitreous hemorrhage increased
in density with further decline in her vision to light perception. She
was therefore taken to the operating room for a pars plana
vitrectomy. Intraoperatively, she was noted to have sclerotic retinal
vasculature inferiorly with evidence of decreased retinal perfusion
and this area was treated with endolaser photocoagulation. She
also received an intravitreal injection of bevacizumab at the end of
the surgery to treat the neovascularization.
One month following surgery, her vision had improved to 20/
200 on the left. Dilated fundus examination revealed a clear vit-
reous cavity. The swelling of the left optic nerve had resolved and
the disc now appeared pale. Her retinopathy had resolved and the
neovascularization had regressed.
The patient provided written consent for publication of personal
information including medical record details and photographs.Fig. 3. Magnetic resonance imaging of the brain. A. Axial T1-weighted image (pre-contras
nerve head. C. Coronal T1-weighted image (post-contrast), showing enhancement of the le3. Discussion
Our case demonstrates the importance of considering not just
the cumulative radiation dose that the optic nerves can tolerate but
also the size of each fraction to minimize the risk of RON. Previous
studies of external beam radiotherapy involving the anterior visual
pathway have demonstrated that single doses of 1.9 Gy or less are
typically safe.8e10 The single-dose tolerance with stereotactic
radiosurgery is estimated to be 8e12 Gy.11e15
The single dose threshold for RON in proton beam treatment has
yet to be deﬁned, though one would expect it to be near that of
photon radiation once adjusted for the increased relative biological
effectiveness.16 A study of 577 patients receiving proton beam
radiotherapy for intraocular tumors identiﬁed a cumulative
threshold dose of 30 cobalt Gy equivalents (CGE, 27.3 proton
Gy  1.1 relative biologic effectiveness) below which the risk of
RON was minimal. Beyond this dose, there was a sharp upturn in
the RON incidence curve with the risk approaching 100% at a cu-
mulative dose of 70 CGE. In this study, treatments were delivered in
5 equal fractions, suggesting that single doses to the optic nerve of 6
CGE or less were well tolerated.17t). B. Axial T1-weighted image (post-contrast), showing enhancement of the left optic
ft optic nerve.
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Our patient received proton beam radiotherapy to a uveal
metastasis in the left macula and subsequently developed RON.
Though the cumulative radiation dose was relatively low, the
treatment was administered in two 10 Gy fractions. While larger
scale studies are needed, this case suggests that smaller fraction-
ated doses of proton beam radiation should be considered when
treating intraocular tumors, particularly in patients receiving con-
current chemotherapy.
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